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Abstract
HIV-1 candidate vaccines expressing an artificial polyprotein comprising Gag, Pol and Nef (GPN) and a secreted envelope
protein (Env) were shown in recent Phase I/II clinical trials to induce high levels of polyfunctional T cell responses; however,
Env-specific responses clearly exceeded those against Gag. Here, we assess the impact of the GPN immunogen design and
variations in the formulation and vaccination regimen of a combined GPN/Env DNA vaccine on the T cell responses against
the various HIV proteins. Subtle modifications were introduced into the GPN gene to increase Gag expression, modify the
expression ratio of Gag to PolNef and support budding of virus-like particles. I.m. administration of the various DNA
constructs into BALB/c mice resulted in an up to 10-fold increase in Gag- and Pol-specific IFNc+ CD8+ T cells compared to
GPN. Co-administering Env with Gag or GPN derivatives largely abrogated Gag-specific responses. Alterations in the molar
ratio of the DNA vaccines and spatially or temporally separated administration induced more balanced T cell responses.
Whereas forced co-expression of Gag and Env from one plasmid induced predominantly Env-specific T cells responses,
deletion of the only H-2d T cell epitope in Env allowed increased levels of Gag-specific T cells, suggesting competition at an
epitope level. Our data demonstrate that the biochemical properties of an artificial polyprotein clearly influence the levels of
antigen-specific T cells, and variations in formulation and schedule can overcome competition for the induction of these
responses. These results are guiding the design of ongoing pre-clinical and clinical trials.
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Introduction
In view of the 2.6 million new HIV infections in 2009 alone,
developing a prophylactic and therapeutic human immunodefi-
ciency virus type-1 (HIV-1) vaccine remains one of the most
desirable objectives of research aimed at controlling the current
AIDS epidemic.
Evidence from natural infection studies with long-term non-
progressors (LTNPs) suggests that substantial CD8+ T cell
responses to Gag are correlated with better control of HIV
infection [1–5]. Hence a variety of T cell based vaccine candidates
are under evaluation.
One recent reversal in HIV-1 vaccine development was the
failure of a clinical efficacy study, the STEP trial [6–8], using a
homologous prime:boost regimen of a 1:1:1 mixture of three
separate replication-defective Ad5 vectors, expressing HIV-1 Gag
(CAM-1 strain), Pol (IIIB strain) and Nef (JR-FL strain). Not only
did the vaccine fail to protect Ad5-seronegative individuals against
infection with HIV-1, or reduce viral load, but further analysis also
suggested that the vaccine might have actually increased
susceptibility to infection in vaccinees with prior immunity to
adenoviruses. A variety of hypotheses were discussed to explain the
increased susceptibility to HIV infection, but the mechanism(s)
responsible for the enhanced sensitivity in vaccine recipients with
high Ad5-NAb titers is still elusive.
In a subsequent Phase III clinical trial, RV-144, also called
Thai-Trial, HIV infections were prevented with a 31% reduced
infection rate among vaccinees compared to the placebo group
[9]. Treatment involved administering the poxvirus ALVAC-HIV
and a recombinant gp120 subunit vaccine (AIDSVAX B/E) in a
heterologous prime:boost regime. Although the vaccine showed no
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34723
effect on the levels of viremia or CD4+ T cell counts in subjects
infected during the study, this clinical trial demonstrated for the
first time that an HIV vaccine is able to prevent HIV infection,
and that recombinant poxvirus vectors are a safe and effective tool
for vaccination in humans.
Several clinical studies, including EV02 and EV03, have since
confirmed in various prime:boost regimens the safety and
immunogenicity of poxviral vectors [10–12]. In the EV02 trial,
some HIV negative volunteers received two injections of an
equimolar mixture of two plasmids encoding an artificial
GagPolNef (DNA-C) polyprotein and the external glycoprotein
gp120 [13], followed by two booster immunizations with a
poxviral (NYVAC) vectored vaccine co-expressing the identical set
of immunogens (NYVAC-C; New York Vaccinia Virus). The
other group received only two NYVAC-C immunizations. Both
the artificial 160 kDa cytoplasmic and nonglycosylated GagPolNef
antigen as well as the secreted form of the viral envelope protein
gp120 were encoded by RNA and codon optimized genes derived
from a previously described clade C virus (CN54) representing the
most prevalent HIV-1 strain circulating throughout China [14].
Whereas the homologous prime:boost with NYVAC-C induced
only marginal antigen-specific T cell responses [15], the
heterologous DNA-C:NYVAC-C prime:boost regimen resulted
in durable (at week 72 in 70% of vaccinees), broad (average
number of 4.2 epitopes per responder) and polyfunctional
(characterized by the production of multiple cytokines, e.g. IFNc
and IL-2) T cell responses, which consisted of both CD4+ and
CD8+ T cells. Notably, these detected T cell responses mimic T
cell profiles seen in LTNPs [10]. Furthermore, a modified DNA-
C:NYVAC-C prime:boost regime in an additional Phase II clinical
trial (EV03) induced the homing of these potentially protective T
cells into the gut [12], which represents the most prominent portal
of entry for HIV.
Despite these encouraging results, EV02 also demonstrated that
Env-specific T cell responses dominated over Gag, Pol, or Nef
specific responses; at week 26, the median of Env-specific IFNc
secreting T cells measured by ELISpot was 299 SFU/106 cells,
whereas Gag, Pol, and Nef responses reached only about 100 SFU
and were no longer detectable at week 48. The same tendencies
were basically observed in pre-clinical trials with both mice and
rhesus macaques [13,16].
Therefore, the aim of this study was to improve T cell responses
directed against the highly conserved Gag and Pol component by
improving the Gag-Pol-Nef immunogen design, and achieve more
balanced T cell responses without affecting the well-induced
gp120-specific responses.
Materials and Methods
Ethics statement
All experiments were conducted in accordance with the legal
requirements of local and national authorities. According to the
German Animal Welfare Act, article 10a, the presented mouse
study did not require the approval by the local authorities, since
exclusively standardized immunization protocols were used. Thus,
notification of the animal studies to the competent authority
(Regierung der Oberpfalz, Bavaria, Germany) two weeks before
beginning was sufficient. All animal studies were supervised by an
animal welfare officer.
Plasmid constructs
The RNA- and codon-optimized GagPolNef and Env gene
constructs were designed by Geneart (Life Technologies) (Regens-
burg, Germany) as described previously [13]. All gene constructs
were finally cloned in a pcDNA3.1 vector under a CMV
promoter. The original Clade C/B9 GagPolNef (GPN) and Env
(gp120) sequences were designed based on sequence information
derived from a 97CN54 provirus clone [14] (Accession Nr.
AX149647). The RNA- and codon-optimized CN54 Env
construct comprises 1500 nucleotides encoding an artificial signal
peptide (MDRAKLLLLLLLLLLPQAQA) [17] followed by gp120
CN54 (nt 5673–7109).
The reference construct 97CN54 GPN, henceforth called
DMGPN, was described recently [10,13,16]. Briefly, it encodes a
,160 kDa non-glycosylated artificial polyprotein comprising (i) a
myristoylation deficient group-specific antigen fused to (ii) the 59
part of pol including the inactivated viral protease, followed by (iii)
a scrambled Nef variant (59 end linked to 39 end) replacing the
active site of the reverse transcriptase, (iv) the 39 pol reading frame
lacking the integrase gene, extended by (v) the 39 end of the
scrambled Nef gene, followed by (vi) a sequence stretch encoding
the active site of the reverse transcriptase.
To restore the competence to form virus-like particles (VLP,
budding competence) the myristoylation signal (A2G) was
replaced, but this did not result in the formation of particles.
Aligning the sequences of 97CN54 with a replication competent
virus isolate (97CN001) from the same patient revealed seven
amino acid exchanges in regions known to be involved in the
aggregation of Gag proteins. Additional substitution of these
amino acids (P66S, L85P, K98R, D309G, R439G, G447R, and
G461E) finally allowed VLP formation. Subsequently, this codon-
optimized Gag sequence was cloned into the KpnI and EcoRI
restriction sites of the reference construct. To restore the HIV
ribosomal frameshift, the frameshift sequence was synthesized by
Geneart (Life Technologies) and subsequently cloned into the AgeI
and BsaBI restriction sites of the reference construct. All new GPN
derivatives, i.e. (i) the construct MGPN encoding the 160 kDa
read-through protein with the myristoylation signal and seven
substituted amino acids within Gag; (ii) DMGFSPN, containing the
original frameshift, and (iii) MGFSPN, containing all the modifi-
cations to restore budding competence and the frameshift
sequence, were cloned via KpnI and XhoI into the expression
vector pcDNA3.1(+) (Invitrogen). Furthermore, the modified Gag
sequence was cloned into the KpnI and EcoRI restriction sites of the
expression vector pcDNA3.1(+) (Invitrogen) resulting in the
construct MGag.
97CN54 PolNef was obtained from the original 97CN54 GPN
construct via PCR and was subsequently cloned into the KpnI and
XhoI restriction sites of the expression vector pcDNA3.1(+)
(Invitrogen) resulting in the construct PN.
Plasmid pQL11 (kind gift from Tim-Henrik Bruun, Regens-
burg) was used to amplify a sequence encoding the human EGFP
(Clontech), the 18 amino acid TaV2a peptide EGRGSLLTCGD-
VEENPGP (called 2a) [18] and the ccdB (synthesized by Geneart
(Life Technologies)) by PCR. The resulting product was subcloned
between the KpnI and XhoI sites of pcDNA3.1(+) (Invitrogen) to
generate the vector pcEGFP-2a-ccdB. The 97CN54 Gag and
CN54 Env (gp120) were obtained from the original pcDNA3.1(+)
vectors via PCR; subsequently, EGFP and ccdB were replaced by
Gag and Env upstream and downstream of 2a, respectively. In
each case, the upstream open reading frame (ORF) lacked the
termination codon, while the downstream ORF is full length.
The pcgp120DV11V construct based on the original CN54 Env
(gp120) was generated by deleting the sequence of the BALB/c
restricted gp120-specific epitope V11V (VPADPNPQEMV) in the
gp120 reading frame. Afterwards, the gene was cloned into
pcDNA3.1(+) (Invitrogen).
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All pDNAs were prepared as supercoiled purified solutions
using Qiagen Megaprep Endo-free kits (Qiagen). For in vivo
application, pDNAs were resuspended in sterile saline solution.
Synthetic peptides
All peptides were purchased from BioSynthan and dissolved in
DMSO at 10 mg/ml. The Gag p24(CA)-derived 9-mer peptide A9I
‘C-clade’ (AMQILKDTI), the Pol derived 9-mer peptide L9I
(LVGPTPVNI) [13] and the gp120 derived 11-mer peptide V11V
(VPADPNPQEMV) [13] were used to assess specific CD8+ T cell
responses.
Cell lines and transfections
293T cells (human embryonal kidney cells, HEK) (DSMZ, no.:
ACC-635) were maintained in Dulbecco’s modified Eagle medium
(Invitrogen) supplemented with 10% fetal calf serum, 2 mM L-
glutamine, 100 IU of penicillin and 100 mg streptomycin per ml.
Cells were seeded into 6-well tissue plates and grown overnight to
80% confluency. Transfection in duplicate wells was performed
using jetPEI transfection reagent (PeqLab) according to the
manufacturer’s instructions. Briefly, cells were transfected with
3 mg of plasmid DNA and 6 ml of jetPEI in a total volume of 2 ml
Dulbecco’s modified Eagle medium (Invitrogen) including 10%
fetal calf serum and 2 mM L-glutamine without antibiotics.
Following 48 h incubation, supernatants were harvested, pelleted
cell lysates collected, and both stored at 220uC. For immuno-
blotting, supernatants were precipitated by adding 100% TCA in
a volume ratio of 1:10 and subsequently washed with 200 ml of
acetone. Cell lysis was performed by incubation with RIPA buffer
for 1 h and a subsequent sonification step.
Immunoblotting
Immunoblotting was performed as described earlier [19]. Gag
and GagPolNef were detected using a p24-specific monoclonal
mouse antibody (CB-4/1, 1:1000) and a horseradish peroxidase-
conjugated goat anti-mouse immunoglobulin G (Dianova;
1:10,000 dilution including 3% milk powder). 97CN54 PolNef
was detected using a HIV-1 RT-specific monoclonal mouse
antibody (clone 5B2B2, HIV molecular immunology database, D.
Helland; 1:400 dilution including 1% milk powder) and a
horseradish peroxidase-conjugated goat anti-mouse immunoglob-
ulin G (Dianova; 1:10,000 dilution including 3% milk powder).
Env CN54 was detected using a gp140-specific monoclonal mouse
antibody (clone MH23, Mark Hassal NIBSC; 1:1,000 dilution
including 1% milk powder) and a horseradish peroxidase-
conjugated goat anti-mouse immunoglobulin G (Dianova;
1:10,000 dilution including 3% milk powder).
Vaccination of mice
Female BALB/c mice (Charles River) were immunized at the
age of 8 to 12 weeks. Groups of 6 mice were immunized by
intramuscular (i.m.) saline injection of 50 ml into both tibialis anterior
muscles. Equimolar amounts of plasmid DNA were applied (unless
indicated otherwise: pcDMGPN, 80 mg; pcMGPN, 80 mg;
pcDMGFSPN, 80 mg; pcMGFSPN, 80 mg; pcGag, 57 mg; pcPN,
68 mg; pcgp120, 57 mg; pcMGag-2a-gp120, 70 mg; pcgp120DV11V,
57 mg). When administering two plasmid DNAs at the same time,
DNA was applied as either a mixture in both legs, or separated
preparations in the left or right leg.
FACS analyses
IFNc expression of CD8+ T cells was detected by intracellular
staining followed by FACS analyses. Splenocytes were stimulated
with 10 mM peptide in RPMI medium or medium alone as a
negative control for 6 h in the presence of Brefeldin A (5 mg/ml).
Intracellular staining was performed as described earlier [20]. In
total, 36104 CD8+ lymphocytes were analyzed.
Intracellular p24- and gp120-specific staining of transfected
293T cells was performed by incubation of permeabilized cells
with fluorochrome-labeled antibodies (anti-p24-antibody, anti-
gp120-antibody HGN194) for 25 min. Anti-p24-antibody was
purchased as a conjugate with Phycoerythrin (clone KC57-RD1,
Beckman Coulter). HGN194 antibody was labeled with ALEXA-
488 (Protein Labeling Kit, Invitrogen) according to the manufac-
turer’s instructions. Cells were analyzed by flow cytometry using
BD FACS Canto II and DIVA 6.0 software (BD).
Results
Since we wanted to improve Gag, (Pol, and Nef)-specific T cell
responses, and achieve more balanced T cell responses directed
against these antigens without affecting the well-induced gp120-
specific responses, we set out to design, generate, and biochem-
ically characterize various modified Gag-Pol-Nef sequences. All
modifications were based on the GPN antigen used for
immunization in the EV02 clinical trial, which was a fusion
protein comprising Gag, Pol and Nef, including some sequence
modifications to enhance its safety profile [13,16]. The main
characteristics of that construct are: (i) in-frame fusion of the polnef
coding sequence to the gag gene resulting in a 160 kDa read-
through protein, and (ii) substitution of the N-terminal glycine by
alanine, which destroyed the myristoylation site, thereby prevent-
ing the budding of virus-like particles (see reference construct,
Fig. 1).
Design and generation of immunologically improved
GPN constructs
To increase expression of the encoded antigens, and at the same
time, allow the budding and release of VLP to support cross
presentation and cross priming events, we introduced a series of
modifications stepwise into the Gag-Pol-Nef coding sequence. To
allowing budding and particle release, we restored the original
myristoylation signal and exchanged seven amino acid sequences
putatively essential for budding, resulting in the construct MGPN
(Fig. 1). Furthermore, the original 97CN54 ribosomal frameshift
sequence with the natural slippery site was reintroduced
(DMGFSPN and MGFSPN), to obtain a predicted Gag:PolNef
expression ratio of between 10:1 to 20:1 [21]. In addition, we
generated constructs allowing expression of the budding compe-
tent Gag (MGag) and PolNef (PN) from separate plasmids (Fig. 1).
The gp120 gene used in the experiments was identical to that
already analyzed in our earlier pre-clinical and clinical studies
[11,13].
Transgene expression of the GPN derivatives and gp120
in 293T cells
To confirm proper expression of the modified antigens, we
transiently transfected human 293T cells with DNA constructs
DMGPN and MGPN, both of which robustly expressed the
160 kDa GPN polyprotein as detected in cell lysates (Fig. 2A).
In addition, MGPN shows a weak band of Pr55Gag, which might
result from residual activity of a modified viral protease triggered
by membrane targeting and assembly.
Introduction of the natural ribosomal frameshift led to efficient
production of Pr55Gag, whereas now only weak signals of the
160 kDa polyprotein GPN were detected, confirming a postulated
10:1 to 20:1 ratio of Gag to GagPolNef resulting from the 21
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frameshift [21]. Due to the overlapping Gag and Pol reading
frame following the frameshift signal, the resulting GPN protein
migrates at a slightly lower molecular weight (compared to
160 kDa) than the read-through constructs DMGPN and MGPN,
where PolNef has been fused to the C-terminus of Gag.
Comparable or even slightly increased synthesis of Pr55Gag was
observed in all lysates after transfection of MGag.
In the supernatants, no Gag-specific products were detected in
the case of DMGPN, MGPN and DMGFSPN, confirming that both
the N-terminal myristoylation, as well as full length 55 kDa Gag
expression are required to drive particle formation and release
(Fig. 2B). In contrast, Gag-specific products could be detected in
the supernatants of cells transfected with MGFSPN or MGag, thus
also confirming earlier data demonstrating that RNA and codon
optimization overcomes restrictions regarding Gag expression
and particle release in murine, monkey as well as human cell lines
[19].
As expected, PolNef was only detectable in the cell lysate and
not in the supernatant (Fig. 2C, D), indicating that there was no
release of PolNef. In contrast, gp120 was readily detected in both
the cell lysate and supernatant (specific bands of lower molecular
weight result from different glycosylation patterns) (Fig. 2E, F).
Budding competence and ribosomal frameshift enhance
Gag- and Pol-specific CD8+ T cell responses
To determine the impact of our modifications on the induction
of specific T cell responses, we inoculated BALB/c mice (n = 6 per
group) i.m. with 80 mg of DMGPN, MGPN, DMGFSPN or MGFSPN.
After 12 days, isolated splenocytes were stimulated in vitro with a
known Gag- or Pol-specific peptide, as well as medium alone as a
negative control. Subsequently, we determined the frequency of
CD8+ IFN-c+ T cells by FACS analysis. Non-immunized BALB/c
mice served as the negative control group (Fig. 3A).
The myristoylation deficient, budding-incompetent reference
construct DMGPN expressing a 160 kDa read-through polypeptide
induced only weak Pol-specific T cell responses, and Gag-specific
responses were scarcely above the background level, affirming
former experiments [13]. Restoring the myristoylation site slightly
increased the number of Gag-specific CD8+ T cells by a factor of
2. Interestingly, Pol-specific T cell responses were enhanced by a
factor of 3, even though the in vitro expression pattern did not
differ compared to DMGPN and no particle release was observed.
Introduction of the original frameshift (MGFSPN) clearly
improved Gag-specific T cell responses, however, at the cost of
the number of Pol-specific CD8+ T cells. This observation
Figure 1. Schematic representation of synthetic expression cassettes derived from gag-pol-nef as well as env (gp120). The reference
construct DMGPN encodes a 160 kDa read-though protein (DFS) comprising the gag-derived domains p17 (matrix), p24 (capsid), p1, p7, p2 and p6*
plus the mutated myristoylation signal (Myr- (GRA)); the pol-derived domains protease (Pr), the N- and C-terminal portions of the reverse
transcriptase (RT-N, RT-C) plus its active site (RT-AS); a scrambled nef (scNEF); and further modifications for safety [13]. MGPN contains a restored
myristoylation signal (Myr+ (ARG)) and additional exchanged sequences of 7 amino acids. To generate DMGFSPN, the original natural frameshift
sequence (+FS) of the CN54 virus isolate was introduced into the DMGPN reference construct. MGFSPN contains both the myristoylation signal/amino
acid exchange modifications and the natural frameshift. MGag contains the Gag sequence with the myristoylation signal and the amino acid
sequence modifications. PN encodes the Pol and Nef domains including all the modifications of these reading frames as in the reference construct.
The codon optimized CN54 derived Env gp120 sequence contains an artificial signal peptide (SP) replacing that of native HIV Env. MGag-2a-gp120
contains the MGag and gp120 reading frames separated by the 18 amino acid TaV2a peptide from Thosea asignia virus. To generate gp120DV11V the
gp120-specific epitope V11V was deleted in the CN54 Env gp120 sequence. All derivatives are under the control of the CMV promoter.
doi:10.1371/journal.pone.0034723.g001
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Figure 2. Protein expression from the modified constructs. 293T cells were transiently transfected with the indicated plasmid DNA constructs
using jetPEI. Cells and supernatants were harvested after 48 h. Cell lysates, and supernatants processed by TCA/acetone precipitation, were separated
by 8.0% SDS-PAGE and analyzed by immunoblotting using p24-specific (Gag) mouse mAb (CB-4/1), HIV-1 RT (Pol)-specific mouse mAb (5B2B2), and
gp120-specific mouse mAb (MH23) to specifically detect the corresponding recombinant polypeptides. Molecular weight markers and positions of
the specifically detected proteins are indicated. mock: non-transfected 293T cells.
doi:10.1371/journal.pone.0034723.g002
Figure 3. Influence of the modified constructs on Gag- and Pol-specific CD8+ T cell immune responses. BALB/c mice (n = 6 per group)
were i.m. inoculated with equimolar amounts of the indicated plasmid DNA constructs (80 mg of DMGPN, MGPN, DMGFSPN, MGFSPN; 57 mg of MGag;
68 mg of PN). After 12 days, spleen cells were isolated and tested for specific cellular immune responses by measuring IFNc production after
stimulation with Gag (black) or Pol (grey) specific peptides. IFNc production was determined by FACS analysis after intracellular staining of IFNc. Cell
culture medium served as a negative control. (A) Influence of budding competence and the functional frameshift on Gag- and Pol-specific CD8+ T cell
immune responses. (B) Impact of separating the Gag and PolNef reading frames on Gag- and Pol-specific CD8+ T cell responses. Data shown are
representative of two experiments.
doi:10.1371/journal.pone.0034723.g003
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correlates with the changed Gag:GagPolNef ratio already detected
above in Western blot analysis. As already seen for MGPN and
DMGPN, also in the case of MGFSPN and DMGFSPN the recovery
of budding competence enhanced both Gag- and Pol-specific
CD8+ T cell responses, but now responses were reversed, with Pol
responses poorer than those to Gag. Remarkably, using a budding
competent Gag-only construct (MGag; Fig. 3B), specific T cell
responses could be enhanced 10-fold in comparison to the
reference construct DMGPN (2336109 compared to 20.5614.8).
Balancing Gag- and Pol-specific immune responses with
multivalent Gag and PolNef vaccine strategies
Besides the above tested constructs encoding Gag, Pol and Nef
linked in an open reading frame, BALB/c mice (n = 6 per group)
were also inoculated with MGag or PolNef (PN) on separate
plasmids. Furthermore, both constructs were mixed at equimolar
amounts or at a Gag:Pol ratio of 20:1 to approximately mimic the
effect of the viral ribosomal frameshift.
As expected, the mixture of MGag and PN in a 20:1 ratio
induced the highest Gag-specific but lower Pol-specific T cell
responses (Fig. 3B), thereby reflecting the tendency already seen in
the frameshift vs. the read-through construct (Fig. 3A). Immuni-
zation with a 1:1 mixture of MGag and PN resulted in a more
balanced, but nevertheless efficient Gag- and Pol-specific immune
responses for both antigens. Administration of MGag and PolNef
(PN) alone led to the induction of Gag- and Pol-specific T cell
responses at levels comparable to the 1:1 mixture immunization.
Co-administration of gp120 reduces Gag- and Pol-
specific CD8+ T cell responses
Next, to evaluate a possible negative impact of Env DNA-
immunization on the outcome of Gag- and Pol-specific T cell
responses following co-administration of GPN and gp120, we
immunized BALB/c mice (n = 6 per group) with MGFSPN or an
equimolar mixture (1:1) of MGag and PN with or without
equimolar amounts of gp120 (1:1:1) (Fig. 4). Interestingly, co-
administration of gp120 dramatically reduced Gag- and Pol-
specific CD8+ T cell responses, in the case of MGFSPN about 7-
fold for both Gag and Pol (Gag: 476679 to 60.5656; Pol:
70.5679 to 1068.5) and in the case of the MGag:PN 1:1 mixture
by at least a factor of 2.6 for Gag (279644 to 105.5691) and 4.5
for Pol (17868.5 to 39.5640). In contrast, Env responses were not
affected, neither by co-immunization of gp120 with MGFSPN nor
with PN or MGag.
To further evaluate whether the rate of Gag- and Pol-specific
immune response reduction depends on the amount of inoculated
gp120, BALB/c mice (n = 6 per group) received an equimolar
mixture of MGag and PN (1:1) as well as decreasing amounts of
gp120 (57, 30, and 10 mg) (Fig. 5, mixture). Correlating with
declining amounts of gp120 encoding plasmid DNA, we detected
decreasing numbers of gp120-specific CD8+ T cells. In contrast,
Gag- and Pol-specific immune responses increased gradually as the
gp120 amount declined, and finally reached CD8+ T cell numbers
comparable to those detected after inoculation of MGag and PN
without gp120. This clearly shows that the level of Gag- and Pol-
specific T cell responses inversely correlates with the amount of co-
administered gp120 plasmid DNA.
Spatial and temporal separation of Gag-Pol-Nef and
gp120 overcome the suppressive effects of Env on Gag-
and Pol-specific CD8+ T cell responses
Subsequently, we evaluated to what extent the suppressive effect
of gp120 co-administration could be overcome by spatial or
temporal separation of the Gag, PN, and gp120 encoding
plasmids. BALB/c mice (n = 6 per group) were immunized with
a mixture of MGag and PN in the tibialis anterior muscle of the left
leg, and different amounts of gp120 (57, 30, or 10 mg) in the right
leg (Fig. 5, separate). In contrast to the gp120-specific T cell
responses, which decreased as expected, the number of Gag- and
Pol-specific CD8+ T cells remained constantly at a level
comparable to the group receiving the mixture of only MGag
and PN.
This result prompted us to analyze the impact of temporally
separated administration of the plasmid DNAs. Here, BALB/c
mice (n = 6 per group) were primed with MGag and PN at day 0
and boosted 14 days later with gp120, or vice versa, primed with
Figure 4. Effect of co-immunization with Gag-Pol-Nef and gp120 on Gag- and Pol-specific CD8+ T cell responses. BALB/c mice (n = 6
per group) were i.m. inoculated (+) with MGFSPN; or equimolar mixtures of MGFSPN and gp120; MGag and PN; or MGag, PN, and gp120. After 12 days,
spleen cells were isolated and tested for specific cellular immune responses by measuring IFNc production after stimulation with Gag (black), Pol
(grey) or Env (hatched) specific peptides as described in Fig. 3. Cell culture medium served as a negative control. Data shown are representative of
two experiments.
doi:10.1371/journal.pone.0034723.g004
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gp120 at day 0 and boosted 2 weeks later with MGag and PN
(Fig. 6). In addition, BALB/c mice received a mixture of MGag
and PN, or a mixture of MGag, PN, and gp120 on day 0 or day 14.
As controls, BALB/c mice were inoculated with gp120 at day 0 or
14, and non-immunized mice served as a negative control.
Whereas co-administration of gp120 at equimolar amounts, as
before, impaired the amount of Gag- and Pol-specific CD8+ T
cells, temporally separated immunization with MGag/PN and
gp120 led to little reduction in the specific immune responses,
generating the same amount of Gag- and Pol-specific T cells as the
mixture of MGag and PN alone.
These experiments clearly demonstrate that, in contrast to
applying a mixture of all three plasmid DNAs, spatially separated
(MGag and PN in the left leg, gp120 in the right) or temporally
separated (day 0 and day 14) administration of the plasmids
overcomes the suppressive effect of gp120 on Gag- and Pol-specific
CD8+ T cell responses.
Linked Gag-Env co-expression confirms suppressive
effects of Env on the induction of Gag-specific T cells
To clarify whether strict co-expression of Gag and gp120 in the
same cell can enhance the level of suppression of Gag-specific
CD8+ T cell responses, we first compared the expression of Gag
and gp120 in vitro using (i) MGag or gp120 separately, (ii) as
mixture, or (iii) both genes linked in-frame via a TaV2a sequence
Figure 5. Spatially separating Gag-Pol-Nef and gp120 alters Gag- and Pol-specific CD8+ T cell responses. BALB/c mice (n = 6 per group)
were i.m. inoculated (+) in both legs with an equimolar mixture of MGag and PN; gp120 alone, or a mixture of MGag, PN and gp120, where the
amount of gp120 was titrated (mixture: 57, 30, 10 mg). Further groups received plasmid DNAs spatially separated as a mixture of MGag and PN in the
right leg and titrated amounts (separate: 57, 30, 10 mg) of gp120 in the left leg. After 12 days, spleen cells were isolated and tested for specific cellular
immune responses by measuring IFNc production after stimulation with Gag (black), Pol (grey) or Env (hatched) specific peptides. IFNc production
was determined by FACS analysis after intracellular staining of IFNc as described in Fig. 3. Cell culture medium served as a negative control. Data
shown are representative of two experiments.
doi:10.1371/journal.pone.0034723.g005
Figure 6. Effect temporal separation of Gag-Pol-Nef and gp120 administration on Gag- and Pol-specific CD8+ T cell responses. BALB/
c mice (n = 6 per group) were i.m. inoculated at day 0 with a mixture of MGag and PN; MGag, PN, and gp120; or MGag and PN, followed by a booster
immunization with gp120 two weeks later (d 14); or vice versa, a mixture of MGag and PN, or MGag, PN and gp120 at day 14; or primed at day 0 with
gp120 followed by a booster immunization with MGag and PN at day 14. At day 29, spleen cells were isolated and tested for specific cellular immune
responses by measuring IFNc production after stimulation with Gag (black), Pol (grey) or Env (hatched) specific peptides. IFNc production was
determined by FACS analysis after intracellular staining of IFNc. Cell culture medium served as a negative control. Data shown are representative of
two experiments.
doi:10.1371/journal.pone.0034723.g006
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on one plasmid for transfecting 293T cells. Initial Western blot
quality controls confirmed that Gag and Env encoded on one
plasmid (MGag-2a-gp120) resulted in Gag and Env expression
levels comparable to the amounts seen if the plasmids encoding
only one antigen were transfected either separately or as a 1:1
equimolar mixture (Fig. 7A).
As demonstrated by FACS analyses, transfection of a mixture of
MGag and gp120-encoding plasmids in 293T cells resulted in
27.1% Gag positive and 10.1% gp120 positive cells, but only 8.3%
of cells were positive for both proteins (Fig. 7B). In contrast, with
MGag-2a-gp120 nearly 27% of all cells expressed both antigens,
whereas only 10% exclusively expressed Gag and only 0.3%
exclusively gp120.
Despite these in vitro differences, Gag-specific T cell responses
were strongly reduced to comparable levels both after adminis-
tration of a mixture of MGag and gp120 and after the inoculation
of MGag-2a-gp120. As before (Fig. 5), the spatial separation of
MGag and gp120 in the left and right leg avoids the suppressive
Figure 7. Expression of Gag and Env in co-transfected 293T cells and the effect of administrating Gag-2a-Env on Gag- and Env-
specific CD8+ T cell responses. (A) 293T cells were transiently transfected with 3 mg of the indicated plasmid DNA constructs. Following 48 h
incubation, TCA-precipitated supernatants and cell lysates were separated by SDS-PAGE and analyzed by immunoblotting using p24-specific (Gag)
mouse mAb (CB-4/1), and gp120-specific mouse mAb (MH23), as indicated. Molecular weight markers and positions of the detected proteins are
indicated. mock: non-transfected 293T cells. (B) 293T cells were transiently transfected with equimolar amounts of the indicated plasmid DNA
constructs. At 48 h post transfection, cells were permeabilized, stained with anti-p24-PE and/or anti-gp120-ALEXA 488 and analyzed by flow
cytometry. (C) BALB/c mice (n = 6 per group) were inoculated i.m. with (i) an equimolar mixture of MGag and gp120 in both legs, (ii) MGag in the left,
and gp120 in the right leg, or (iii) MGag-2a-gp120. After 12 days, spleen cells were isolated and tested for specific cellular immune responses by
measuring IFNc production after stimulation with Gag (black) and Env (hatched) specific peptides as above. IFNc production was determined using
FACS analysis after intracellular staining of IFNc. Cell culture medium served as negative control. Data shown are representative of two experiments.
doi:10.1371/journal.pone.0034723.g007
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effect of gp120 on the number of of Gag-specific CD8+ T cells
(Fig. 7C).
Thus, assuming that only a fraction of successfully transduced
cells expresses both Gag and Env, direct competition for
expression or a direct interaction of Gag and gp120 in the
expressing cell seems unlikely to be responsible for the negative
effect of Env on the induction of Gag-specific T cell responses.
However, the physical proximity of both antigens, e.g. in the
muscle or in the draining lymph node, with an Env, that can be
secreted from transduced cells, seems to be crucial for the observed
suppression of Gag-specific T cell responses.
Deletion of the BALB/c specific epitope of gp120
prevents the reduction of Gag-specific T cells after co-
administration
One study [22] already demonstrated that HIV Env interferes
with the presentation of a CMV-specific CTL epitope at the level
of MHC class I mediated presentation of antigenic epitopes.
To evaluate a potential interference between Env and Gag at
the level of peptide processing and presentation, the only known
H-2d restricted epitope (V11V) within the clade C CN54 envelope
protein [13] was deleted, resulting in the gp120DV11V construct
(Fig. 1). Subsequently, BALB/c mice (n = 6 per group) were
immunized with (i) equimolar amounts of MGag, gp120, or
gp120DV11V plasmid DNA constructs, (ii) an equimolar mixture of
MGag and gp120, or (iii) an equimolar mixture of MGag and
gp120DV11V (Fig. 8). As expected, co-administration of MGag and
gp120 reduced the numbers of Gag-specific T cells by about a
factor of 2.3 (446622 to 19069), but did not significantly alter the
number of induced Env-specific T cells. In contrast, levels of
induced Gag-specific T cell responses following application of a
mixture of MGag and gp120DV11V were fairly high compared to
the group receiving MGag alone.
Thus, deleting the gp120-specific V11V epitope from the gp120
reading frame preserves the Gag-specific T cell responses following
co-administration of MGag and gp120DV11V. This suggests that
competition between the Gag and gp120 antigen is most probably
a result of peptide competition of the Gag-specific epitope A9I and
the gp120-specific V11V for H-2d restricted MHC class I epitope
presentation.
Discussion
As we have shown recently, application of our first generation
HIV vaccine candidates DNA-C followed by booster immuniza-
tions with NYVAC-C, induced strong, broad and polyfunctional T
cell responses in pre-clinical [13,16] as well as clinical studies
[10,11,12]. Unexpectedly, the induced T cell responses were
predominantly directed against Env, whereas Gag-, Pol- and Nef-
specific responses were less frequent and of lower magnitude.
Here, we set out to resolve this by modifying (i) the encoded
antigens, (ii) the formulation, and (iii) immunization regimens to
allow induction of improved Gag-, Pol- and Nef-specific T cell
responses without affecting Env-specific reactivity.
Restoring the N-terminal Gag-myristoylation signal did not
alter protein expression levels significantly, nor did it support
formation and release of GPN particles due to the nature of this
160 kDa read-through protein. Nevertheless, this modification
enhanced Gag- (,2-fold) and Pol- (,3-fold) specific T cell
responses suggesting that alteration of intracellular trafficking,
folding and/or interaction of the artificial GPN polyprotein
precursor resulting from the N-terminal modification might
positively impact processing of class I-restricted T cell epitopes
[23].
In comparison to DMGPN, re-introduction of the natural
ribosomal frameshift, resulting in a postulated 10:1 to 20:1
expression ratio of Gag:GPN [21], increased the level of Pr55 Gag
expression, which translated into an increased number of Gag-
specific T cells (,6-fold). The level of Pol-specific T cell responses
was only marginally reduced, which can be attributed to an overall
higher protein expression compensating for the relatively lower Pol
amounts compared to Gag.
The strongest Gag-specific T cell responses were observed
following restoration of the budding competence, as well as
enabling ribosomal frameshifting, which results in the release of
VLP consisting of 90–95% Gag (,2000 Gag molecules) and 5–
10% GagPolNef (MGagFSPN) [24,25]. In this case, T cell
responses were enhanced by a factor of 10 or more compared to
the parental 160 kDa GPN. These data also nicely correlate with
the results obtained after applying a 20:1 molar mixture of Gag
and PN on separated plasmids. An equimolar mixture of the latter
Figure 8. Impact of deleting the BALB/c immunodominant gp120 epitope V11V on Gag-specific CD8+ T cell immune responses.
BALB/c mice (n = 6 per group) were i.m. inoculated with (i) equimolar amounts of the indicated plasmid DNA construct (57 mg of MGag, gp120,
gp120DV11V), (ii) an equimolar mixture of MGag and gp120, or (iii) an equimolar mixture of MGag and gp120DV11V. After 12 days, spleen cells were
isolated and tested for specific cellular immune responses by measuring IFNc production after stimulation with Gag (black) or Env (hatched) specific
peptides. IFNc production was determined using FACS analysis after intracellular staining of IFNc. Cell culture medium served as negative control.
Data shown are representative of two experiments.
doi:10.1371/journal.pone.0034723.g008
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constructs resulted in more balanced Gag- and Pol-specific T cell
responses. Taken together, we were able to substantially increase
Gag and PolNef protein expression levels in vitro and Gag- and
Pol-specific T cell responses in vivo by (i) restoring the budding
competence of Gag, (ii) re-introducing the natural viral frameshift
or (iii) delivering Gag and PolNef via separate plasmids.
It is widely accepted that the combination of several antigens
covering a wide spectrum of epitopes is the most promising
strategy to induce broad immune responses directed against HIV.
However, we observed in both humans and non-human primates
[10,16] a bias towards strong Env- and weak Gag-specific T cell
responses upon co-administration of Gag and Env immunogens
via viral and non-viral vectors. A second objective of this study was
therefore to reveal a potential negative interference between Gag-
and Env-specific immune responses, and to elaborate strategies
allowing the induction of more balanced T cell responses.
First we compared antigen-specific CD8+ T cell responses
induced after administering MGagFSPN or MGag with those
detected after applying an equimolar mixture with gp120
encoding plasmid DNA. Co-administration of G/PN DNA mixed
with the Env DNA resulted in a 2 to 10-fold decrease in Gag- and
Pol-specific T cell responses, depending on the exact nature of the
analyzed Gag, PN or GPN construct. Accordingly, the negative
impact of Env on the stimulation of Gag- and Pol-specific T cell
responses could be overcome by reducing the levels of Env
encoding plasmid in the DNA vaccine mixture, thus altering the
molar ratios of Env vs. Gag and PN. Furthermore, the negative
effects on Gag-related CTL responses could be completely
overcome by temporal or spatial separation of gp120 and Gag
encoding plasmid DNAs.
Mechanisms underlying the observed Env-mediated suppression
of T cell responses against other antigens are controversially
discussed, and depending on the experimental design range from
competition for expression [26], suppression of expression via e.g.
type 1 IFN [27], Env-mediated suppression of DC activation and
maturation [28], to epitope competition [22].
Along these lines, Hovav et al. [27] recently reported
suppression of ovalbumin (Ova) or luciferase (Luc) expression in
vivo when co-administered with an Env expression plasmid. This
was accompanied by significantly reduced Ova- or Luc-specific
cellular immune responses, whereby gp120-specific responses
remained unaffected. Clearly in contrast to our own results as
well as earlier findings by Toapanta et al. [26], this negative gp120
driven effect could not be overcome by injecting the different
constructs into separate hind legs. The authors speculated that a
soluble factor such as type 1 IFN, known to be produced by
plasmacytoid DC triggered by gp120 [29], and to down-regulate
the activity of the cytomegalovirus promoter they utilized [30],
might account for the observed phenomenon.
An earlier publication reported Ld-restricted competition
between co-expressed gp160 and CMV pp89 at the level of
MHC-peptide assembly [22]. Here, we could clearly show that
administering an equimolar MGag/Env plasmid mixture, or one
plasmid physically linking Gag and Env expression resulted in a
comparable reduction of Gag-specific T cell responses, even
though our in vitro analyses reveal that co-immunization of MGag
and Env plasmids results in a substantial proportion of cells
expressing exclusively Gag or Env (Fig. 7). Although the in vivo
situation could differ from the data generated in vitro, these results
also indicate that the expression of both antigens in one cell, e.g. a
muscle cell, is not a stringent prerequisite for their interference.
Interestingly, deletion of the only known H-2d gp120 epitope
V11V within the CN54 Env abolished the negative impact of
gp120 on the induction of Gag-specific T cell responses, returning
levels of Gag-specific T cells back to those seen in mice receiving
the MGag plasmid only (Fig. 8). Therefore, it seems highly
improbable that Env either directly [26] or indirectly [27], e.g. via
type 1 IFNs, negatively interferes with Gag expression, thus
suppressing induction of Gag-specific T cells. Furthermore, our
data also seem to exclude the possibility that an inhibitory effect of
Env on DC maturation and activation causes the observed
suppression of Gag-specific T cells [28].
Rather, the results presented here suggest that the Gag and Env
epitopes compete for H-2d MHC class I presentation. Our in vitro
data strongly support the hypothesis that gp120 can be efficiently
secreted from successfully transduced cells, and can therefore - in a
distinct lymphatic compartment - end up together with Gag or
GPN in the same antigen presenting cell, where MHC
competition might happen. This idea is strongly supported by
the observation that temporal or spatial separation can resolve the
observed negative interference.
In conclusion, our data demonstrate that the biochemical
properties of an artificial polyprotein clearly influence the levels of
antigen-specific T cells, and variations in administered formulation
and schedule can overcome competition for the induction of
antigen-specific T cell responses. The results of this study have
guided the design of ongoing pre-clinical and clinical trials.
Author Contributions
Conceived and designed the experiments: KB JW SB KK JK RW.
Performed the experiments: KB JW SB. Analyzed the data: KB JW SB.
Wrote the paper: KB JW RW.
References
1. Cao Y, Qin L, Zhang L, Safrit J, Ho DD (1995) Virologic and immunologic
characterization of long-term survivors of human immunodeficiency virus type 1
infection. N Engl J Med 332: 201–208.
2. Ferre AL, Hunt PW, Critchfield JW, Young DH, Morris MM, et al. (2009)
Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of
immune control. Blood 113: 3978–3989.
3. Gandhi RT, Walker BD (2002) Immunologic control of HIV-1. Annu Rev Med
53: 149–172.
4. Harrer T, Harrer E, Kalams SA, Barbosa P, Trocha A, et al. (1996) Cytotoxic T
lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection.
Breadth and specificity of the response and relation to in vivo viral quasispecies
in a person with prolonged infection and low viral load. J Immunol 156:
2616–2623.
5. Wagner R, Leschonsky B, Harrer E, Paulus C, Weber C, et al. (1999) Molecular
and functional analysis of a conserved CTL epitope in HIV-1 p24 recognized
from a long-term nonprogressor: constraints on immune escape associated with
targeting a sequence essential for viral replication. J Immunol 162: 3727–3734.
6. Cohen J (2007) AIDS research. Promising AIDS vaccine’s failure leaves field
reeling. Science 318: 28–29.
7. Cohen J (2007) AIDS research. Did Merck’s failed HIV vaccine cause harm?
Science 318: 1048–1049.
8. Ledford H (2007) HIV vaccine may raise risk. Nature 450: 325.
9. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al.
(2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in
Thailand. N Engl J Med 361: 2209–2220.
10. Harari A, Bart PA, Stohr W, Tapia G, Garcia M, et al. (2008) An HIV-1 clade
C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional,
and long-lasting T cell responses. J Exp Med 205: 63–77.
11. McCormack S, Stohr W, Barber T, Bart PA, Harari A, et al. (2008) EV02: a
Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-
NYVAC-C boost to NYVAC-C alone. Vaccine 26: 3162–3174.
12. Perreau M, Welles HC, Harari A, Hall O, Martin R, et al. (2011) DNA/
NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses
in intestinal mucosa. J Virol 85: 9854–9862.
13. Wild J, Bieler K, Ko¨stler J, Frachette MJ, Jeffs S, et al. (2009) Preclinical
evaluation of the immunogenicity of C-type HIV-1-based DNA and NYVAC
vaccines in the BALB/c mouse model. Viral Immunol 22: 309–319.
Optimized HIV-1 Clade C DNA Vaccine
PLoS ONE | www.plosone.org 10 April 2012 | Volume 7 | Issue 4 | e34723
14. Su L, Graf M, Zhang Y, von Briesen H, Xing H, et al. (2000) Characterization
of a virtually full-length human immunodeficiency virus type 1 genome of a
prevalent intersubtype (C/B9) recombinant strain in china. J Virol 74:
11367–11376.
15. Bart PA, Goodall R, Barber T, Harari A, Guimaraes-Walker A, et al. (2008)
EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C
HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine
26: 3153–3161.
16. Mooij P, Balla-Jhagjhoorsingh SS, Beenhakker N, van Haaften P, Baak I, et al.
(2009) Comparison of human and rhesus macaque T-cell responses elicited by
boosting with NYVAC encoding human immunodeficiency virus type 1 clade C
immunogens. J Virol 83: 5881–5889.
17. Berglund P, Quesada-Rolander M, Putkonen P, Biberfeld G, Thorstensson R, et
al. (1997) Outcome of immunization of cynomolgus monkeys with recombinant
Semliki Forest virus encoding human immunodeficiency virus type 1 envelope
protein and challenge with a high dose of SHIV-4 virus. AIDS Res Hum
Retroviruses 13: 1487–1495.
18. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, et al. (2004)
Correction of multi-gene deficiency in vivo using a single ‘self-cleaving’ 2A
peptide-based retroviral vector. Nat Biotechnol 22: 589–594.
19. Deml L, Bojak A, Steck S, Graf M, Wild J, et al. (2001) Multiple effects of codon
usage optimization on expression and immunogenicity of DNA candidate
vaccines encoding the human immunodeficiency virus type 1 Gag protein.
J Virol 75: 10991–11001.
20. Bojak A, Wild J, Deml L, Wagner R (2002) Impact of codon usage modification
on T cell immunogenicity and longevity of HIV-1 gag-specific DNA vaccines.
Intervirology 45: 275–286.
21. Staple DW, Butcher SE (2003) Solution structure of the HIV-1 frameshift
inducing stem-loop RNA. Nucleic Acids Res 31: 4326–4331.
22. Lopez D, Samino Y, Koszinowski UH, del Val M (2001) HIV envelope protein
inhibits MHC class I presentation of a cytomegalovirus protective epitope.
J Immunol 167: 4238–4244.
23. Yuan X, Yu X, Lee TH, Essex M (1993) Mutations in the N-terminal region of
human immunodeficiency virus type 1 matrix protein block intracellular
transport of the Gag precursor. J Virol 67: 6387–6394.
24. Haffar O, Garrigues J, Travis B, Moran P, Zarling J, et al. (1990) Human
immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a
recombinant vaccinia virus expression system. J Virol 64: 2653–2659.
25. Wagner R, Fliessbach H, Wanner G, Motz M, Niedrig M, et al. (1992) Studies
on processing, particle formation, and immunogenicity of the HIV-1 gag gene
product: a possible component of a HIV vaccine. Arch Virol 127: 117–137.
26. Toapanta FR, Craigo JK, Montelaro RC, Ross TM (2007) Reduction of anti-
HIV-1 Gag immune responses during co-immunization: immune interference
by the HIV-1 envelope. Curr HIV Res 5: 199–209.
27. Hovav AH, Santosuosso M, Bivas-Benita M, Plair A, Cheng A, et al. (2009) X4
human immunodeficiency virus type 1 gp120 down-modulates expression and
immunogenicity of codelivered antigens. J Virol 83: 10941–10950.
28. Martinelli E, Cicala C, Van Ryk D, Goode Dj, Macleod K, et al. (2007) HIV-1
gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in
plasmacytoid dendritic cells. Proc Natl Acad Sci U S A 104: 3396–3401.
29. Schmidt B, Ashlock BM, Foster H, Fujimura SH, Levy JA (2005) HIV-infected
cells are major inducers of plasmacytoid dendritic cell interferon production,
maturation, and migration. Virology 343: 256–266.
30. Sellins K, Fradkin L, Liggitt D, Dow S (2005) Type I interferons potently
suppress gene expression following gene delivery using liposome(-)DNA
complexes. Mol Ther 12: 451–459.
Optimized HIV-1 Clade C DNA Vaccine
PLoS ONE | www.plosone.org 11 April 2012 | Volume 7 | Issue 4 | e34723
